Werewolf Therapeutics, Inc. (HOWL)
Nasdaq: HOWL · Pharmaceutical Preparations · Watertown, MA · filing with the SEC since 2019
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Mar 27, 2026 | Mar 11, 2025 | Mar 7, 2024 | Mar 23, 2023 | Mar 24, 2022 | · |
| Research and development | 44,830 | 56,434 | 41,776 | 53,761 | 35,269 | 16,641 |
| General and administrative | 15,847 | 19,045 | 18,670 | 18,696 | 14,818 | 5,763 |
| Total operating expenses | 60,677 | 75,479 | 60,446 | 72,457 | 50,087 | 22,404 |
| Operating income | -60,677 | -73,594 | -40,503 | -56,056 | -50,087 | -22,404 |
| Interest expense | 5,274 | 4,656 | 3,139 | 0 | · | · |
| Interest and investment income | 3,108 | 6,673 | 7,416 | 1,908 | 104 | 63 |
| Other income (expense), net | 2,021 | 1,615 | -1,142 | 338 | · | · |
| Total non-operating income (expense) | -145 | 3,079 | 3,135 | 2,246 | 104 | 7,364 |
| Income tax expense | 0 | · | · | · | · | · |
| Net income | -60,822 | -70,515 | -37,368 | -53,810 | -49,983 | -15,040 |
| Net income to common shareholders | -60,822 | -70,515 | -37,368 | -53,810 | -201,925 | -28,217 |
| Earnings per share, basic | -1.32 | -1.63 | -1.05 | -1.86 | -10.94 | -28.08 |
| Earnings per share, diluted | -1.33 | -1.63 | -1.05 | -1.86 | -10.94 | -28.08 |
| Weighted average shares, basic | 46,018,888 | 43,332,088 | 35,646,572 | 28,863,935r | 18,455,000 | 1,005,000 |
| Weighted average shares, diluted | 46,810,252 | 43,859,664 | 35,646,572 | 28,863,935r | 18,455,000 | 1,005,000 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterest
us-gaap:InvestmentIncomeNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding